Previous 10 | Next 10 |
ST. LOUIS, April 18, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open ...
ST. LOUIS, April 13, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (R...
ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderda...
Stereotaxis, Inc. (STXS) Q4 2022 Earnings Conference Call March 3, 2023 10:00 AM ET Company Participants David Fischel - CEO & Chairman Kimberly Peery - CFO & Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Frank Takkinen -...
Stereotaxis press release ( NYSE: STXS ): Q4 GAAP EPS of -$0.06 beats by $0.01 . Revenue of $7.3M (-11.0% Y/Y) misses by $1.2M . At December 31, 2022, Stereotaxis had cash and investments, including restricted cash, of $29.7 million and no debt. "We started 2023 wi...
ST. LOUIS, March 03, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022. “This year is ...
Stereotaxis ( NYSE: STXS ) is scheduled to announce Q4 earnings results on Friday, March 3nd, before market open. The consensus EPS Estimate is -$0.07 (-40.0% Y/Y) and the consensus Revenue Estimate is $8.5M (+3.7% Y/Y). Over the last 1 year, STXS has beaten EPS estimates ...
Major earning expected before the bell on Friday include: Deutsche Lufthansa ( OTCQX:DLAKF ) Hibbett ( HIBB ) inTEST ( INTT ) OFS Capital ( OFS ) Oncolytics Biotech ( ONCY ) SNC-Lavalin Group ( OTCPK:SNCAF ) Stereotaxis ( STXS ) For Se...
ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Cowen 43 rd Annual Health Care Conference...
Summary Stereotaxis, Inc. stock fell in 2022 because of new product delays and weak new orders. These delays and disappointing new orders were caused by macro headwinds that are abating. There are many catalysts in 2023. The Magic catheter getting the CE Mark should turn investor sentim...
News, Short Squeeze, Breakout and More Instantly...
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Gene...
ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation...
ST. LOUIS, May 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac ...